アトピー性皮膚炎(Atopic Dermatitis):世界の治験レビュー(2016年上半期版)

調査会社GlobalData社が発行したリサーチレポート(データ管理コード:GDHC3226CTIDB)
◆英語タイトル:Atopic Dermatitis Global Clinical Trials Review, H1, 2016
◆発行会社/調査会社:GlobalData
◆商品コード:GDHC3226CTIDB
◆発行日:2016年2月
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:355
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[アトピー性皮膚炎(Atopic Dermatitis):世界の治験レビュー(2016年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界におけるアトピー性皮膚炎(Atopic Dermatitis) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - アトピー性皮膚炎(Atopic Dermatitis)
  - 当レポートの概要
・アトピー性皮膚炎(Atopic Dermatitis):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
*** レポート概要(サマリー)***

Atopic Dermatitis Global Clinical Trials Review, H1, 2016

Summary

GlobalData’s clinical trial report, “Atopic Dermatitis Global Clinical Trials Review, H1, 2016″ provides an overview of Atopic Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Atopic Dermatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Atopic Dermatitis to Dermatology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Atopic Dermatitis to Dermatology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Atopic Dermatitis Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Atopic Dermatitis 29
Jan 08, 2016: Anacor Pharmaceuticals to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference 29
Dec 29, 2015: Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis 29
Dec 10, 2015: Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients 29
Nov 23, 2015: Alexar Therapeutics Initiates Phase IIa Clinical Trial for ALX-101 Topical Gel 30
Clinical Trial Profile Snapshots 31
Appendix 352
Abbreviations 352
Definitions 352
Research Methodology 353
Secondary Research 353
About GlobalData 354
Contact Us 354
Disclaimer 354
Source 355

List of Tables
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Atopic Dermatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Atopic Dermatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Atopic Dermatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Atopic Dermatitis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Atopic Dermatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Atopic Dermatitis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Atopic Dermatitis to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Atopic Dermatitis to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Atopic Dermatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Atopic Dermatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Atopic Dermatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Atopic Dermatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Atopic Dermatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Atopic Dermatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Atopic Dermatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Atopic Dermatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Atopic Dermatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Atopic Dermatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Atopic Dermatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Atopic Dermatitis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Atopic Dermatitis to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Atopic Dermatitis to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Atopic Dermatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Atopic Dermatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Atopic Dermatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Atopic Dermatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Atopic Dermatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Atopic Dermatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Atopic Dermatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 353

*** 掲載企業 ***

Novartis AG
Regeneron Pharmaceuticals, Inc.
Astellas Pharma Inc.
Sanofi
GlaxoSmithKline Plc
The LEO Foundation
Bayer AG
F. Hoffmann-La Roche Ltd.
Anacor Pharmaceuticals, Inc.
Johnson & Johnson

*** レポートのキーワード ***

アトピー性皮膚炎(Atopic Dermatitis)、治験、臨床試験、治験、治療薬

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDHC3226CTIDB )"アトピー性皮膚炎(Atopic Dermatitis):世界の治験レビュー(2016年上半期版)" (英文:Atopic Dermatitis Global Clinical Trials Review, H1, 2016)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。